Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

Submission Guidelines

Style and Format

File format

Manuscript files can be in the following formats: DOC, DOCX, or RTF. Microsoft Word documents should not be locked or protected. 

LaTeX manuscripts must be submitted as PDFs. Read the LaTeX guidelines.

Length

Manuscripts can be any length. There are no restrictions on word count, number of figures, or amount of supporting information.


We encourage you to present and discuss your findings concisely.

Font

Use a standard font size and any standard font, except for the font named “Symbol”. To add symbols to the manuscript, use the Insert → Symbol function in your word processor or paste in the appropriate Unicode character.

Headings

Limit manuscript sections and sub-sections to 3 heading levels. Make sure heading levels are clearly indicated in the manuscript text.

Layout and spacing

Manuscript text should be double-spaced.

Do not format text in multiple columns.

Page and line numbers

Include page numbers and line numbers in the manuscript file. Use continuous line numbers (do not restart the numbering on each page).

Footnotes

Footnotes are not permitted. If your manuscript contains footnotes, move the information into the main text or the reference list, depending on the content.

Language

Manuscripts must be submitted in English. 

You may submit translations of the manuscript or abstract as supporting information. Read the supporting information guidelines.

Abbreviations

Define abbreviations upon first appearance in the text.

Do not use non-standard abbreviations unless they appear at least three times in the text.

Keep abbreviations to a minimum.

Reference style

PLOS uses “Vancouver” style, as outlined in the ICMJE sample references.

See reference formatting examples and additional instructions below.

Equations

We recommend using MathType for display and inline equations, as it will provide the most reliable outcome. If this is not possible, Equation Editor or Microsoft's Insert→Equation function is acceptable.

Avoid using MathType, Equation Editor, or the Insert→Equation function to insert single variables (e.g., “a² + b² = c²”), Greek or other symbols (e.g., β, Δ, or ′ [prime]), or mathematical operators (e.g., x, ≥, or  ±) in running text. Wherever possible, insert single symbols as normal text with the correct Unicode (hex) values.

Do not use MathType, Equation Editor, or the Insert→Equation function for only a portion of an equation. Rather, ensure that the entire equation is included. Equations should not contain a mix of different equation tools. Avoid “hybrid” inline or display equations, in which part is text and part is MathType, or part is MathType and part is Equation Editor.

Nomenclature

 Use correct and established nomenclature wherever possible.

Units of measurement Use SI units. If you do not use these exclusively, provide the SI value in parentheses after each value. Read more about SI units.
Drugs Provide the Recommended International Non-Proprietary Name (rINN).
Species names Write in italics (e.g., Homo sapiens). Write out in full the genus and species, both in the title of the manuscript and at the first mention of an organism in a paper. After first mention, the first letter of the genus name followed by the full species name may be used (e.g., H. sapiens).
Genes, mutations, genotypes, and alleles Write in italics. Use the recommended name by consulting the appropriate genetic nomenclature database (e.g., HGNC for human genes; we strongly recommend using this tool to check against previously approved names). It is sometimes advisable to indicate the synonyms for the gene the first time it appears in the text. Gene prefixes such as those used for oncogenes or cellular localization should be shown in roman typeface (e.g., v-fes, c-MYC).
Allergens

The systematic allergen nomenclature of the World Health Organization/International Union of Immunological Societies (WHO/IUIS) Allergen Nomenclature Sub-committee should be used for manuscripts that include the description or use of allergenic proteins. For manuscripts describing new allergens, the systematic name of the allergen should be approved by the WHO/IUIS Allergen Nomenclature Sub-Committee prior to manuscript publication. Examples of the systematic allergen nomenclature can be found at the WHO/IUIS Allergen Nomenclature site.

Copyediting manuscripts

Prior to submission, authors who believe their manuscripts would benefit from professional editing are encouraged to use language-editing and copyediting services. Obtaining this service is the responsibility of the author, and should be done before initial submission. These services can be found on the web using search terms like “scientific editing service” or “manuscript editing service.”

Submissions are not copyedited before publication.

Submissions that do not meet the PLOS ONE publication criterion for language standards may be rejected.

Manuscript Organization

Manuscripts should be organized as follows. Instructions for each element appear below the list.

Beginning section

The following elements are required, in order:

  • Title page: List title, authors, and affiliations as first page of the manuscript
  • Abstract
  • Introduction
Middle section

The following elements can be renamed as needed and presented in any order:

  • Materials and Methods
  • Results
  • Discussion
  • Conclusions (optional)
Ending section

The following elements are required, in order:

  • Acknowledgments
  • References
  • Supporting information captions (if applicable)
Other elements
  • Figure captions are inserted immediately after the first paragraph in which the figure is cited. Figure files are uploaded separately.
  • Tables are inserted immediately after the first paragraph in which they are cited.
  • Supporting information files are uploaded separately.

 

  Refer to our downloadable sample files to ensure that your submission meets our formatting requirements:

Viewing Figures and Supporting Information in the compiled submission PDF
The compiled submission PDF includes low-resolution preview images of the figures after the reference list. The function of these previews is to allow you to download the entire submission as quickly as possible. Click the link at the top of each preview page to download a high-resolution version of each figure. Links to download Supporting Information files are also available after the reference list.

Parts of a Submission

Title

Include a full title and a short title for the manuscript.

Title Length Guidelines Examples
Full title 250 characters Specific, descriptive, concise, and comprehensible to readers outside the field

Impact of cigarette smoke exposure on innate immunity: A Caenorhabditis elegans model

Solar drinking water disinfection (SODIS) to reduce childhood diarrhoea in rural Bolivia: A cluster-randomized, controlled trial

Short title 100 characters State the topic of the study

Cigarette smoke exposure and innate immunity

SODIS and childhood diarrhoea

Titles should be written in sentence case (only the first word of the text, proper nouns, and genus names are capitalized). Avoid specialist abbreviations if possible. For clinical trials, systematic reviews, or meta-analyses, the subtitle should include the study design.

Author list

Authorship requirements

All authors must meet the criteria for authorship as outlined in the authorship policy. Those who contributed to the work but do not meet the criteria for authorship can be mentioned in the Acknowledgments. Read more about Acknowledgments.

The corresponding author must provide an ORCID iD at the time of submission by entering it in the user profile in the submission system. Read more about ORCID.

Author names and affiliations

Enter author names on the title page of the manuscript and in the online submission system.

On the title page, write author names in the following order:

  • First name (or initials, if used)
  • Middle name (or initials, if used)
  • Last name (surname, family name)

Each author on the list must have an affiliation. The affiliation includes department, university, or organizational affiliation and its location, including city, state/province (if applicable), and country. Authors have the option to include a current address in addition to the address of their affiliation at the time of the study. The current address should be listed in the byline and clearly labeled “current address.” At a minimum, the address must include the author’s current institution, city, and country.

If an author has multiple affiliations, enter all affiliations on the title page only. In the submission system, enter only the preferred or primary affiliation. Author affiliations will be listed in the typeset PDF article in the same order that authors are listed in the submission.

Author names will be published exactly as they appear in the manuscript file. Please double-check the information carefully to make sure it is correct.

Corresponding author

The submitting author is automatically designated as the corresponding author in the submission system. The corresponding author is the primary contact for the journal office and the only author able to view or change the manuscript while it is under editorial consideration.

The corresponding author role may be transferred to another coauthor. However, note that transferring the corresponding author role also transfers access to the manuscript. (To designate a new corresponding author while the manuscript is still under consideration, watch the video tutorial below.)

Only one corresponding author can be designated in the submission system, but this does not restrict the number of corresponding authors that may be listed on the article in the event of publication. Whoever is designated as a corresponding author on the title page of the manuscript file will be listed as such upon publication. Include an email address for each corresponding author listed on the title page of the manuscript.

Consortia and group authorship

If a manuscript is submitted on behalf of a consortium or group, include its name in the manuscript byline. Do not add it to the author list in the submission system. You may include the full list of members in the Acknowledgments or in a supporting information file.

PubMed only indexes individual consortium or group author members listed in the article byline. If included, these individuals must qualify for authorship according to our criteria.

Author contributions

Provide at minimum one contribution for each author in the submission system. Use the CRediT taxonomy to describe each contribution. Read the policy and the full list of roles.

Contributions will be published with the final article, and they should accurately reflect contributions to the work. The submitting author is responsible for completing this information at submission, and we expect that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time.

PLOS ONE will contact all authors by email at submission to ensure that they are aware of the submission.

Cover letter

Upload a cover letter as a separate file in the online system. The length limit is 1 page.

The cover letter should include the following information:

  • Summarize the study’s contribution to the scientific literature
  • Relate the study to previously published work
  • Specify the type of article (for example, research article, systematic review, meta-analysis, clinical trial)
  • Describe any prior interactions with PLOS regarding the submitted manuscript
  • Suggest appropriate Academic Editors to handle your manuscript (see the full list of Academic Editors)
  • List any opposed reviewers

IMPORTANT: Do not include requests to reduce or waive publication fees in the cover letter. This information will be entered separately in the online submission system.

Read about publication fee assistance.

Title page

The title, authors, and affiliations should all be included on a title page as the first page of the manuscript file.  

Abstract

The Abstract comes after the title page in the manuscript file. The abstract text is also entered in a separate field in the submission system.  

The Abstract should:

  • Describe the main objective(s) of the study
  • Explain how the study was done, including any model organisms used, without methodological detail
  • Summarize the most important results and their significance
  • Not exceed 300 words

Abstracts should not include:

  • Citations
  • Abbreviations, if possible

Introduction

The introduction should:

  • Provide background that puts the manuscript into context and allows readers outside the field to understand the purpose and significance of the study
  • Define the problem addressed and why it is important
  • Include a brief review of the key literature
  • Note any relevant controversies or disagreements in the field
  • Conclude with a brief statement of the overall aim of the work and a comment about whether that aim was achieved

Materials and Methods

The Materials and Methods section should provide enough detail to allow suitably skilled investigators to fully replicate your study. Specific information and/or protocols for new methods should be included in detail. If materials, methods, and protocols are well established, authors may cite articles where those protocols are described in detail, but the submission should include sufficient information to be understood independent of these references.

Supporting reproducibility with protocols

To enhance the reproducibility of your results, we recommend and encourage you to make your protocols public. There are several options:

Protocols associated with Research Articles

Protocol documents may be uploaded as Supporting Information or linked from the Methods section of the article. For laboratory protocols, we recommend protocols.io. Include the DOI link in the Methods section of your manuscript using the following format: http://dx.doi.org/10.17504/protocols.io.[PROTOCOL DOI]. This allows editors and reviewers to consult the detailed step-by-step protocol when evaluating your manuscript. You can choose to keep the protocol private on the protocols.io platform until your article is published—at which time it will be published automatically. 

Protocols published in their own right

PLOS ONE offers two options for publishing stand-alone protocol articles: Lab Protocols that describe reusable methodologies and Study Protocols that describe detailed plans and proposals for research projects. Specific guidelines apply to the submission of Lab Protocol and Study Protocol manuscripts. Read the detailed instructions for submitting Lab Protocols and Study Protocols.

 

Results, Discussion, Conclusions

These sections may all be separate, or may be combined to create a mixed Results/Discussion section (commonly labeled “Results and Discussion”) or a mixed Discussion/Conclusions section (commonly labeled “Discussion”). These sections may be further divided into subsections, each with a concise subheading, as appropriate. These sections have no word limit, but the language should be clear and concise.

Together, these sections should describe the results of the experiments, the interpretation of these results, and the conclusions that can be drawn.

Authors should explain how the results relate to the hypothesis presented as the basis of the study and provide a succinct explanation of the implications of the findings, particularly in relation to previous related studies and potential future directions for research.

PLOS ONE editorial decisions do not rely on perceived significance or impact, so authors should avoid overstating their conclusions. See the PLOS ONE Criteria for Publication for more information.

Acknowledgments

Those who contributed to the work but do not meet our authorship criteria should be listed in the Acknowledgments with a description of the contribution.

Authors are responsible for ensuring that anyone named in the Acknowledgments agrees to be named.

PLOS journals publicly acknowledge the indispensable efforts of our editors and reviewers on an annual basis. To ensure equitable recognition and avoid any appearance of partiality, do not include editors or peer reviewers—named or unnamed—in the Acknowledgments.

Do not include funding sources in the Acknowledgments or anywhere else in the manuscript file. Funding information should only be entered in the financial disclosure section of the submission system.

References

Any and all available works can be cited in the reference list. Acceptable sources include:

  • Published or accepted manuscripts
  • Manuscripts on preprint servers, providing the manuscript has a citable DOI or arXiv URL.

Do not cite the following sources in the reference list:

  • Unavailable and unpublished work, including manuscripts that have been submitted but not yet accepted (e.g., “unpublished work,” “data not shown”). Instead, include those data as supplementary material or deposit the data in a publicly available database.
  • Personal communications (these should be supported by a letter from the relevant authors but not included in the reference list)
  • Submitted research should not rely upon retracted research. You should avoid citing retracted articles unless you need to discuss retracted work to provide historical context for your submitted research. If it is necessary to discuss retracted work, state the article’s retracted status in your article’s text and reference list.

Ensure that your reference list includes full and current bibliography details for every cited work at the time of your article’s submission (and publication, if accepted). If cited work is corrected, retracted, or marked with an expression of concern before your article is published, and if you feel it is appropriate to cite the work even in light of the post-publication notice, include in your manuscript citations and full references for both the affected article and the post-publication notice. Email the journal office if you have questions.

References are listed at the end of the manuscript and numbered in the order that they appear in the text. In the text, cite the reference number in square brackets (e.g., “We used the techniques developed by our colleagues [19] to analyze the data”). PLOS uses the numbered citation (citation-sequence) method and first six authors, et al.

Do not include citations in abstracts. 

Make sure the parts of the manuscript are in the correct order before ordering the citations.

Formatting references

Because all references will be linked electronically as much as possible to the papers they cite, proper formatting of references is crucial. 

PLOS uses the reference style outlined by the International Committee of Medical Journal Editors (ICMJE), also referred to as the “Vancouver” style. Example formats are listed below. Additional examples are in the ICMJE sample references.

A reference management tool, EndNote, offers a current style file that can assist you with the formatting of your references. If you have problems with any reference management program, please contact the source company's technical support.

Journal name abbreviations should be those found in the National Center for Biotechnology Information (NCBI) databases

Source Format
Published articles

Hou WR, Hou YL, Wu GF, Song Y, Su XL, Sun B, et al. cDNA, genomic sequence cloning and overexpression of ribosomal protein gene L9 (rpL9) of the giant panda (Ailuropoda melanoleuca). Genet Mol Res. 2011;10: 1576-1588.

Devaraju P, Gulati R, Antony PT, Mithun CB, Negi VS. Susceptibility to SLE in South Indian Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 genes. Mol Immunol. 2014 Nov 22. pii: S0161-5890(14)00313-7. doi: 10.1016/j.molimm.2014.11.005.


Note: A DOI number for the full-text article is acceptable as an alternative to or in addition to traditional volume and page numbers. When providing a DOI, adhere to the format in the example above with both the label and full DOI included at the end of the reference (doi: 10.1016/j.molimm.2014.11.005). Do not provide a shortened DOI or the URL.
Accepted, unpublished articles Same as published articles, but substitute “Forthcoming” for page numbers or DOI.
Online articles

Huynen MMTE, Martens P, Hilderlink HBM. The health impacts of globalisation: a conceptual framework. Global Health. 2005;1: 14. Available from: http://www.globalizationandhealth.com/content/1/1/14

Books

Bates B. Bargaining for life: A social history of tuberculosis. 1st ed. Philadelphia: University of Pennsylvania Press; 1992.

Book chapters Hansen B. New York City epidemics and history for the public. In: Harden VA, Risse GB, editors. AIDS and the historian. Bethesda: National Institutes of Health; 1991. pp. 21-28.
Deposited articles (preprints, e-prints, or arXiv)

Krick T, Shub DA, Verstraete N, Ferreiro DU, Alonso LG, Shub M, et al. Amino acid metabolism conflicts with protein diversity. arXiv:1403.3301v1 [Preprint]. 2014 [cited 2014 March 17]. Available from: https://128.84.21.199/abs/1403.3301v1​

Kording KP, Mensh B. Ten simple rules for structuring papers. BioRxiv [Preprint]. 2016 bioRxiv 088278 [posted 2016 Nov 28; revised 2016 Dec 14; revised 2016 Dec 15; cited 2017 Feb 9]: [12 p.]. Available from: https://www.biorxiv.org/content/10.1101/088278v5 doi: 10.1101/088278

Published media (print or online newspapers and magazine articles) Fountain H. For Already Vulnerable Penguins, Study Finds Climate Change Is Another Danger. The New York Times. 2014 Jan 29 [Cited 2014 March 17]. Available from: http://www.nytimes.com/2014/01/30/science/earth/climate-change-taking-toll-on-penguins-study-finds.html
New media (blogs, web sites, or other written works) Allen L. Announcing PLOS Blogs. 2010 Sep 1 [cited 17 March 2014]. In: PLOS Blogs [Internet]. San Francisco: PLOS 2006 - . [about 2 screens]. Available from: http://blogs.plos.org/plos/2010/09/announcing-plos-blogs/.
Masters' theses or doctoral dissertations Wells A. Exploring the development of the independent, electronic, scholarly journal. M.Sc. Thesis, The University of Sheffield. 1999. Available from: http://cumincad.scix.net/cgi-bin/works/Show?2e09
Databases and repositories (Figshare, arXiv) Roberts SB. QPX Genome Browser Feature Tracks; 2013 [cited 2013 Oct 5]. Database: figshare [Internet]. Available from: http://figshare.com/articles/QPX_Genome_Browser_Feature_Tracks/701214
Multimedia (videos, movies, or TV shows) Hitchcock A, producer and director. Rear Window [Film]; 1954. Los Angeles: MGM.

Supporting information

Authors can submit essential supporting files and multimedia files along with their manuscripts. All supporting information will be subject to peer review. All file types can be submitted, but files must be smaller than 20 MB in size.

Authors may use almost any description as the item name for a supporting information file as long as it contains an “S” and number. For example, “S1 Appendix” and “S2 Appendix,” “S1 Table” and “S2 Table,” and so forth.  

Supporting information files are published exactly as provided, and are not copyedited.

Supporting information captions

List supporting information captions at the end of the manuscript file. Do not submit captions in a separate file.

The file number and name are required in a caption, and we highly recommend including a one-line title as well. You may also include a legend in your caption, but it is not required.

Example caption

S1 Text. Title is strongly recommended.
 Legend is optional.

In-text citations

We recommend that you cite supporting information in the manuscript text, but this is not a requirement. If you cite supporting information in the text, citations do not need to be in numerical order.

Read the supporting information guidelines for more details about submitting supporting information and multimedia files.

Figures and tables

Figures

Do not include figures in the main manuscript file. Each figure must be prepared and submitted as an individual file.

Cite figures in ascending numeric order at first appearance in the manuscript file.

Figure captions

Figure captions must be inserted in the text of the manuscript, immediately following the paragraph in which the figure is first cited (read order). Do not include captions as part of the figure files themselves or submit them in a separate document.

At a minimum, include the following in your figure captions:

  • A figure label with Arabic numerals, and “Figure” abbreviated to “Fig” (e.g. Fig 1, Fig 2, Fig 3, etc). Match the label of your figure with the name of the file uploaded at submission (e.g. a figure citation of “Fig 1” must refer to a figure file named “Fig1.tif”).
  • A concise, descriptive title

The caption may also include a legend as needed.

Tables

Cite tables in ascending numeric order upon first appearance in the manuscript file.

Place each table in your manuscript file directly after the paragraph in which it is first cited (read order). Do not submit your tables in separate files.

Tables require a label (e.g., “Table 1”) and brief descriptive title to be placed above the table. Place legends, footnotes, and other text below the table. 

Statistical reporting

Manuscripts submitted to PLOS ONE are expected to report statistical methods in sufficient detail for others to replicate the analysis performed. Ensure that results are rigorously reported in accordance with community standards and that statistical methods employed are appropriate for the study design.

Consult the following resources for additional guidance:

  • SAMPL guidelines, for general guidance on statistical reporting
  • PLOS ONE guidelines, for clinical trials requirements
  • PLOS ONE guidelines, for systematic review and meta-analysis requirements
  • EQUATOR, for specific reporting guidelines for a range of other study types

Reporting of statistical methods

In the methods, include a section on statistical analysis that reports a detailed description of the statistical methods. In this section:

  • List the name and version of any software package used, alongside any relevant references
  • Describe technical details or procedures required to reproduce the analysis
  • Provide the repository identifier for any code used in the analysis (See our code-sharing policy.)

Statistical reporting guidelines:

  • Identify research design and independent variables as being between- or within-subjects
  • For pre-processed data:
    • Describe any analysis carried out to confirm the data meets the assumptions of the analysis performed (e.g. linearity, co-linearity, normality of the distribution).
    • If data were transformed include this information, with a reason for doing so and a description of the transformation performed
  • Provide details of how outliers were treated and your analysis, both with the full dataset and with the outliers removed
  • If relevant, describe how missing/excluded data were handled
  • Define the threshold for significance (alpha)
  • If appropriate, provide sample sizes, along with a description of how they were determined. If a sample size calculation was performed, specify the inputs for power, effect size and alpha. Where relevant, report the number of independent replications for each experiment.
  • For analyses of variance (ANOVAs), detail any post hoc tests that were performed
  • Include details of any corrections applied to account for multiple comparisons. If corrections were not applied, include a justification for not doing so
  • Describe all options for statistical procedures. For example, if t-tests were performed, state whether these were one- or two-tailed. Include details of the type of t-test conducted (e.g. one sample, within-/between-subjects).
  • For step-wise multiple regression analyses:
    • Report the alpha level used
    • Discuss whether the variables were assessed for collinearity and interaction
    • Describe the variable selection process by which the final model was developed (e.g., forward-stepwise; best subset). See SAMPL guidelines.
  • For Bayesian analysis explain the choice of prior trial probabilities and how they were selected. Markov chain Monte Carlo settings should be reported.

Reporting of statistical results

Results must be rigorously and appropriately reported, in keeping with community standards.

  • Units of measurement. Clearly define measurement units in all tables and figures.
  • Properties of distribution. It should be clear from the text which measures of variance (standard deviation, standard error of the mean, confidence intervals) and central tendency (mean, median) are being presented.
  • Regression analyses. Include the full results of any regression analysis performed as a supplementary file. Include all estimated regression coefficients, their standard error, p-values, and confidence intervals, as well as the measures of goodness of fit.
  • Reporting parameters. Test statistics (F/t/r) and associated degrees of freedom should be provided. Effect sizes and confidence intervals should be reported where appropriate. If percentages are provided, the numerator and denominator should also be given.
  • P-values. Report exact p-values for all values greater than or equal to 0.001. P-values less than 0.001 may be expressed as p < 0.001, or as exponentials in studies of genetic associations.
  • Displaying data in plots. Format plots so that they accurately depict the sample distribution. 3D effects in plots can bias and hinder interpretation of values, so avoid them in cases where regular plots are sufficient to display the data.
  • Open data. As explained in PLOS’s Data Policy, be sure to make individual data points, underlying graphs and summary statistics available at the time of publication. Data can be deposited in a repository or included within the Supporting Information files.

Data reporting

All data and related metadata underlying the findings reported in a submitted manuscript should be deposited in an appropriate public repository, unless already provided as part of the submitted article.

See instructions on providing underlying data to support blot and gel results.

Repositories may be either subject-specific (where these exist) and accept specific types of structured data, or generalist repositories that accept multiple data types. We recommend that authors select repositories appropriate to their field. Repositories may be subject-specific (e.g., GenBank for sequences and PDB for structures), general, or institutional, as long as DOIs or accession numbers are provided and the data are at least as open as CC BY. Authors are encouraged to select repositories that meet accepted criteria as trustworthy digital repositories, such as criteria of the Centre for Research Libraries or Data Seal of Approval. Large, international databases are more likely to persist than small, local ones.

To support data sharing and author compliance of the PLOS data policy, we have integrated our submission process with a select set of data repositories. The list is neither representative nor exhaustive of the suitable repositories available to authors. Current repository integration partners include Dryad and FlowRepository. Please contact data@plos.org to make recommendations for further partnerships.

Instructions for PLOS submissions with data deposited in an integration partner repository:

  • Deposit data in the integrated repository of choice.
  • Once deposition is final and complete, the repository will provide you with a dataset DOI (provisional) and private URL for reviewers to gain access to the data.
  • Enter the given data DOI into the full Data Availability Statement, which is requested in the Additional Information section of the PLOS submission form. Then provide the URL passcode in the Attach Files section.

If you have any questions, please email us.

Accession numbers

All appropriate data sets, images, and information should be deposited in an appropriate public repository. See our list of recommended repositories.

Accession numbers (and version numbers, if appropriate) should be provided in the Data Availability Statement. Accession numbers or a citation to the DOI should also be provided when the data set is mentioned within the manuscript.

In some cases authors may not be able to obtain accession numbers of DOIs until the manuscript is accepted; in these cases, the authors must provide these numbers at acceptance. In all other cases, these numbers must be provided at full submission.

Identifiers

As much as possible, please provide accession numbers or identifiers for all entities such as genes, proteins, mutants, diseases, etc., for which there is an entry in a public database, for example:

Identifiers should be provided in parentheses after the entity on first use.

Striking image

You can choose to upload a “Striking Image” that we may use to represent your article online in places like the journal homepage or in search results.

The striking image must be derived from a figure or supporting information file from the submission, i.e., a cropped portion of an image or the entire image. Striking images should ideally be high resolution, eye-catching, single panel images, and should ideally avoid containing added details such as text, scale bars, and arrows.

If no striking image is uploaded, we will designate a figure from the submission as the striking image.

Striking images should not contain potentially identifying images of people. Read our policy on identifying information.

The PLOS licenses and copyright policy also applies to striking images.

Additional Information Requested at Submission

Financial Disclosure Statement

This information should describe sources of funding that have supported the work. It is important to gather these details prior to submission because your financial disclosure statement cannot be changed after initial submission without journal approval. If your manuscript is published, your statement will appear in the Funding section of the article.

Enter this statement in the Financial Disclosure section of the submission form. Do not include it in your manuscript file.

The statement should include:

  • Specific grant numbers
  • Initials of authors who received each award
  • Full names of commercial companies that funded the study or authors
  • Initials of authors who received salary or other funding from commercial companies
  • URLs to sponsors’ websites

Also state whether any sponsors or funders (other than the named authors) played any role in:

  • Study design
  • Data collection and analysis
  • Decision to publish
  • Preparation of the manuscript

If they had no role in the research, include this sentence: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

If the study was unfunded, include this sentence as the Financial Disclosure statement: “The author(s) received no specific funding for this work."

Competing interests

This information should not be in your manuscript file; you will provide it via our submission system.

All potential competing interests must be declared in full. If the submission is related to any patents, patent applications, or products in development or for market, these details, including patent numbers and titles, must be disclosed in full.

Manuscripts disputing published work

For manuscripts disputing previously published work, it is PLOS ONE policy to invite a signed review by the disputed author during the peer review process. This procedure is aimed at ensuring a thorough, transparent, and productive review process.

If the disputed author chooses to submit a review, it must be returned in a timely fashion and contain a full declaration of all competing interests. The Academic Editor will consider any such reviews in light of the competing interest.

Authors submitting manuscripts disputing previous work should explain the relationship between the manuscripts in their cover letter, and will be required to confirm that they accept the conditions of this review policy before the manuscript is considered further.

Related manuscripts

Upon submission, authors must confirm that the manuscript, or any related manuscript, is not currently under consideration or accepted elsewhere. If related work has been submitted to PLOS ONE or elsewhere, authors must include a copy with the submitted article. Reviewers will be asked to comment on the overlap between related submissions.

We strongly discourage the unnecessary division of related work into separate manuscripts, and we will not consider manuscripts that are divided into “parts.” Each submission to PLOS ONE must be written as an independent unit and should not rely on any work that has not already been accepted for publication. If related manuscripts are submitted to PLOS ONE, the authors may be advised to combine them into a single manuscript at the editor's discretion.

Read our policies on related manuscripts.

Preprints

PLOS encourages authors to post preprints to accelerate the dissemination of research. Posting a manuscript on a preprint server does not impact consideration of the manuscript at any PLOS journal.

Authors posting preprints on bioRxiv or medRxiv can choose to concurrently submit their manuscripts to relevant PLOS journals through the direct transfer service.

Authors submitting manuscripts in the life and health sciences to PLOS ONE may choose to have PLOS forward their submission to bioRxiv or medRxiv, depending on the scope of the paper, for consideration for posting as a preprint.

Guidelines for Specific Study Types

Study design, reporting, and analyses are assessed against all relevant research and methodological technique standards held by the community. Guidelines for specific study types are outlined below.

Registered Reports

Submission and format requirements for Registered Report Protocols and Registered Reports are similar to those for a regular submission and may be specific to your study type. For instance, if your Registered Report Protocol submission is about a Clinical Trial or a Systematic Review, follow the appropriate guidelines.

For Registered Report Protocols:

  • Provide enough methodological detail to make the study reproducible and replicable
  • Confirm that data will be made available upon study completion in keeping with the PLOS Data policy
  • Include ethical approval or waivers, if applicable
  • Preliminary or pilot data may be included, but only if necessary to support the feasibility of the study or as a proof of principle 
  • For meta-analyses or Clinical Trials, use the protocol-specific reporting guidelines PRISMA-P or SPIRIT respectively

For more guidance on format and presentation of a protocol, consult the sample template hosted by the Open Science Framework. Discipline-specific and study-specific templates are also available.

If data need to be collected, modified or processed specifically for your study, or if participants need to be recruited specifically for your study, then it should occur only after your Registered Report Protocol is accepted for publication.


For Registered Report Research Articles:

  • Report the results of all planned analyses and, if relevant, detail and justify all deviations from the protocol. 
  • The manuscript may also contain exploratory, unplanned analyses.

Read more about Registered Report framework.

Human subjects research

All research involving human participants must have been approved by the authors’ Institutional Review Board (IRB) or by equivalent ethics committee(s), and must have been conducted according to the principles expressed in the Declaration of Helsinki. Authors should be able to submit, upon request, a statement from the IRB or ethics committee indicating approval of the research. We reserve the right to reject work that we believe has not been conducted to a high ethical standard, even when formal approval has been obtained.

Subjects must have been properly instructed and have indicated that they consent to participate by signing the appropriate informed consent paperwork. Authors may be asked to submit a blank, sample copy of a subject consent form. If consent was verbal instead of written, or if consent could not be obtained, the authors must explain the reason in the manuscript, and the use of verbal consent or the lack of consent must have been approved by the IRB or ethics committee.

All efforts should be made to protect patient privacy and anonymity. Identifying information, including photos, should not be included in the manuscript unless the information is crucial and the individual has provided written consent by completing the Consent Form for Publication in a PLOS Journal (PDF). Download additional translations of the form here. More information about patient privacy, anonymity, and informed consent can be found in the International Committee of Medical Journal Editors (ICMJE) Privacy and Confidentiality guidelines.

Manuscripts should conform to the following reporting guidelines:

  • Studies of diagnostic accuracy: STARD
  • Observational studies: STROBE
  • Microarray experiments: MIAME
  • Other types of health-related research: Consult the EQUATOR web site for appropriate reporting guidelines

Methods sections of papers on research using human subjects or samples must include ethics statements that specify:

  • The name of the approving institutional review board or equivalent committee(s). If approval was not obtained, the authors must provide a detailed statement explaining why it was not needed
  • Whether informed consent was written or oral. If informed consent was oral, it must be stated in the manuscript:
    • Why written consent could not be obtained
    • That the Institutional Review Board (IRB) approved use of oral consent
    • How oral consent was documented

For studies involving humans categorized by race/ethnicity, age, disease/disabilities, religion, sex/gender, sexual orientation, or other socially constructed groupings, authors should:

  • Explicitly describe their methods of categorizing human populations
  • Define categories in as much detail as the study protocol allows
  • Justify their choices of definitions and categories, including for example whether any rules of human categorization were required by their funding agency
  • Explain whether (and if so, how) they controlled for confounding variables such as socioeconomic status, nutrition, environmental exposures, or similar factors in their analysis

In addition, outmoded terms and potentially stigmatizing labels should be changed to more current, acceptable terminology. Examples: “Caucasian” should be changed to “white” or “of [Western] European descent” (as appropriate); “cancer victims” should be changed to “patients with cancer.”

For papers that include identifying, or potentially identifying, information, authors must download the Consent Form for Publication in a PLOS Journal, which the individual, parent, or guardian must sign once they have read the paper and been informed about the terms of PLOS open-access license. The signed consent form should not be submitted with the manuscript, but authors should securely file it in the individual's case notes and the methods section of the manuscript should explicitly state that consent authorization for publication is on file, using wording like:

The individual in this manuscript has given written informed consent (as outlined in PLOS consent form) to publish these case details.

For more information about PLOS ONE policies regarding human subjects research, see the Publication Criteria and Editorial Policies.

Manuscripts describing observational clinical studies are subject to all policies regarding human research and community standards for reporting observational research as outlined by the STROBE statement. Furthermore, authors submitting work of this nature should pay special attention to the following requirements:

  • If the submitted manuscript is very similar to previous work, authors must provide a sound scientific rationale for the submitted work and clearly reference and discuss the existing literature.
  • The sampling strategy and eligibility criteria of enrolled subjects should be described in sufficient detail.
  • Sample size calculations should be justified with relevant inputs defined.
  • Independent and dependent variables considered for statistical analysis should be clearly defined and justified.
  • The validity and reliability testing of self-developed data collection tools should be reported.
  • Conclusions should be appropriate for the study design, with indications on how the study results will contribute to the base of academic knowledge.

Clinical trials

Clinical trials are subject to all policies regarding human researchPLOS ONE follows the World Health Organization's (WHO) definition of a clinical trial:

A clinical trial is any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes [...] Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc.

All clinical trials must be registered in one of the publicly-accessible registries approved by the WHO or ICMJE (International Committee of Medical Journal Editors). Authors must provide the trial registration number. Prior disclosure of results on a clinical trial registry site will not affect consideration for publication. We reserve the right to inform authors' institutions or ethics committees, and to reject the manuscript, if we become aware of unregistered trials.

PLOS ONE supports prospective trial registration (i.e. before participant recruitment has begun) as recommended by the ICMJE's clinical trial registration policyWhere trials were not publicly registered before participant recruitment began, authors must:

  • Register all related clinical trials and confirm they have done so in the Methods section
  • Explain in the Methods the reason for failing to register before participant recruitment

Clinical trials must be reported according to the relevant reporting guidelines, i.e. CONSORT for randomized controlled trials, TREND for non-randomized trials, and other specialized guidelines as appropriate. The intervention should be described according to the requirements of the TIDieR checklist and guide. Submissions must also include the study protocol as supporting information, which will be published with the manuscript if accepted.

Authors of manuscripts describing the results of clinical trials must adhere to the CONSORT reporting guidelines appropriate to their trial design, available on the CONSORT Statement web site. Before the paper can enter peer review, authors must:

  • The name of the registry and the registration number must be included in the Abstract.
  • Provide a copy of the trial protocol as approved by the ethics committee and a completed CONSORT checklist as supporting information (which will be published alongside the paper, if accepted). This should be named S1 CONSORT Checklist.
  • Include the CONSORT flow diagram as the manuscript's “Fig 1”

Any deviation from the trial protocol must be explained in the paper. Authors must explicitly discuss informed consent in their paper, and we reserve the right to ask for a copy of the patient consent form.

The name of the registry and the registry number must be provided in the Abstract. If the trial is registered in more than one location, please provide all relevant registry names and numbers.

Lab Protocols

Lab Protocols consist of two interlinked components: a step-by-step protocol hosted on protocols.io, and a peer-reviewed article in PLOS ONE that contextualises the protocol.

 

protocols.io is a secure platform for developing and sharing reproducible methods. It enables scientists to make, exchange, improve, and discuss protocols for specific experimental procedures. The platform provides specialized tools for communicating technical details, including reagents, measurements, and formulae.

 

The PLOS ONE article component must comply with the general PLOS ONE submission guidelines (detailed above) and criteria for publication. In addition, the PLOS ONE article component should:

  • Describe the value that the protocol adds to the published literature. Lab Protocols describing routine methods or extensions and modifications of routine methods that add little value to the published literature will not be considered for publication.
  • Provide evidence that the protocol works, by either:
    • Linking, in the Introduction section, to at least one supporting peer-reviewed publication in which the protocol was applied to generate data.
      or
    • Providing validation or benchmarking data, which demonstrates that the underlying method achieves its intended purpose.
  • Provide the step-by-step protocol as a supporting information (S1) file. 

We encourage you to post your protocol to the protocols.io platform before submitting your manuscript to PLOS ONE. Posting your protocol prior to submission is not considered prior publication by PLOS ONE and will not affect your eligibility to publish a Lab Protocol.

Authors submitting a Lab Protocol can also use protocols.io’s protocol entry service at no cost: the team at protocols.io will enter your protocol for you and format it in a way that takes advantage of the platform’s features. You will have an opportunity to review and make further changes before your protocol is shared with anyone else. 

If you would like to use protocols.io's protocol entry service in connection with a Lab Protocol submission, please contact plosone@plos.org to request the customer code.

If you prefer to submit your manuscript to PLOS ONE before posting your protocol to protocols.io, then you must still provide your step-by-step protocol as a supporting information (S1) file in a format of your choosing. You will be expected to replace this file with a protocols.io PDF later in the editorial process.

Study Protocols

Study Protocols describe plans for conducting research projects and consist of a single article on PLOS ONE.

Study Protocols must comply with the PLOS ONE general submission guidelines (detailed above in this article) and any guidelines specific to the related research study type. In addition, the protocol must:

Additional prerequisites apply for these study types:

  • Clinical trials:
     
    • The trial must be registered prior to submission of your protocol in one of the publicly accessible registries approved by the WHO or ICMJE (International Committee of Medical Journal Editors).
    • The name of the registry and the trial or study registration number must be included in the Abstract.
    • A copy of the protocol that was approved by the ethics committee must be submitted as a supplementary information file. Please provide an additional English translation if the original document is not in English. Please note that the protocol will be published with the manuscript if accepted.
    • A SPIRIT schedule of enrollment, interventions, and assessments must be included as the manuscript’s Figure 1, and a completed SPIRIT checklist must be uploaded as Supporting Information file S1.
  • Systematic reviews and meta-analyses:
     

Study Protocols must also comply with general PLOS ONE criteria for publication and in addition you should:

  • include the word “Protocol” in your Title.
  • include a detailed description of the planned study in the Materials and Methods section.This should provide sufficient methodological detail for the protocol to be reproducible and replicable. Your description should cover all relevant and applicable facts and hypothesis, including:
     
    • the aim, design, and settling
    • the sample size calculation
    • how data saturation will be determined (for qualitative studies)
    • the characteristics of participants e.g., inclusion and exclusion criteria, sample selection criteria, variables to be measured, randomization and blinding criteria (where applicable), and how informed consent will be obtained 
    • how materials will be selected and used e.g., where and how they will be sourced, the processes, interventions, or comparisons to be used, the outcomes to be measured, and when and how they will be measured
    • the data management plan
    • safety considerations
    • the type of data and statistical analyses to be used
    • the status and timeline of the study, including whether participant recruitment or data collection has begun
    • where and when the data will be made available. See our Data Availability policy for more.
  • include an analysis of preliminary or pilot data, only if it is necessary to support the feasibility of the study or as a proof of principle. This is optional.
  • we encourage authors you to register with OSF and provide the your registration number in the Materials and Methods section. This is optional.
  • optionally add any other SI files, figures or tables that elaborate or authenticate the protocol: e.g., any reporting checklists applicable to your study type.

Read the supporting information guidelines for more details about adding SI files.

Study Protocols are subject to the same editorial and peer review process as all other articles, and are eligible for both signed and published peer review.

You can expedite the review process by providing:

 
  • proof of external funding. This is typically your funding approval letter and a list of the names and credentials of the funders who conducted the external peer review of the protocol. Include an English translation if needed.
  • proof of ethics approval (if required). This is typically the approval or waiver letter from the relevant ethics body and a copy of the protocol approved by this body. 

The proof of external funding and approval or waiver letter are used for internal purposes and do not form part of the published Study Protocol.
Expedited review is conducted by an internal Staff Editor only and bypasses the external review process. 

If the Study Protocol describes a replication study or involves re-analysis of published work, we will invite the author of the initial or replicated study to provide a signed review. 

 

We encourage you to share your Study Protocol with other researchers, either before or after submission. You can publish it on your website or protocols.io, or submit it for posting on medRxiv or another preprint server.

 

Animal research

All research involving vertebrates or cephalopods must have approval from the authors' Institutional Animal Care and Use Committee (IACUC) or equivalent ethics committee(s), and must have been conducted according to applicable national and international guidelines. Approval must be received prior to beginning research.

Manuscripts reporting animal research must state in the Methods section:

  • The full name of the relevant ethics committee that approved the work, and the associated permit number(s).
  • Where ethical approval is not required, the manuscript should include a clear statement of this and the reason why. Provide any relevant regulations under which the study is exempt from the requirement for approval.
  • Relevant details of steps taken to ameliorate animal suffering.
Example ethics statement


This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by the Committee on the Ethics of Animal Experiments of the University of Minnesota (Protocol Number: 27-2956). All surgery was performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering.

Authors should always state the organism(s) studied in the Abstract. Where the study may be confused as pertaining to clinical research, authors should also state the animal model in the title.

To maximize reproducibility and potential for re-use of data, we encourage authors to follow the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines for all submissions describing laboratory-based animal research and to upload a completed ARRIVE Guidelines Checklist to be published as supporting information.

Non-human primates

Manuscripts describing research involving non-human primates must report details of husbandry and animal welfare in accordance with the recommendations of the Weatherall report, The use of non-human primates in research, including:

  • Information about housing, feeding, and environmental enrichment.
  • Steps taken to minimize suffering, including use of anesthesia and method of sacrifice, if appropriate.

Random source animals

Manuscripts describing studies that use random source (e.g. Class B dealer-sourced in the USA), shelter, or stray animals will be subject to additional scrutiny and may be rejected if sufficient ethical and scientific justification for the study design is lacking.

Unacceptable euthanasia methods and anesthetic agents

Manuscripts reporting use of a euthanasia method(s) classified as unacceptable by the American Veterinary Medical Association or use of an anesthesia method(s) that is widely prohibited (e.g., chloral hydrate, ether, chloroform) must include at the time of initial submission, scientific justification for use in the specific study design, as well as confirmation of approval for specific use from their animal research ethics committee. These manuscripts may be subject to additional ethics considerations prior to publication.

Humane endpoints

Manuscripts reporting studies in which death of a regulated animal (vertebrate, cephalopod) is a likely outcome or a planned experimental endpoint, must comprehensively report details of study design, rationale for the approach, and methodology, including consideration of humane endpoints. This applies to research that involves, for instance, assessment of survival, toxicity, longevity, terminal disease, or high rates of incidental mortality.

Definition of a humane endpoint

A humane endpoint is a predefined experimental endpoint at which animals are euthanized when they display early markers associated with death or poor prognosis of quality of life, or specific signs of severe suffering or distress. Humane endpoints are used as an alternative to allowing such conditions to continue or progress to death following the experimental intervention (“death as an endpoint”), or only euthanizing animals at the end of an experiment. Before a study begins, researchers define the practical observations or measurements that will be used during the study to recognize a humane endpoint, based on anticipated clinical, physiological, and behavioral signs. Please see the NC3Rs guidelines for more information. Additional discussion of humane endpoints can be found in this article: Nuno H. Franco, Margarida Correia-Neves, I. Anna S. Olsson (2012) How “Humane” Is Your Endpoint? — Refining the Science-Driven Approach for Termination of Animal Studies of Chronic Infection. PLoS Pathog 8(1): e1002399 doi.org/10.1371/journal.ppat.1002399.

Full details of humane endpoints use must be reported for a study to be reproducible and for the results to be accurately interpreted.

For studies in which death of an animal is an outcome or a planned experimental endpoint, authors should include the following information in the Methods section of the manuscript:

  • The specific criteria (i.e. humane endpoints) used to determine when animals should be euthanized.
  • The duration of the experiment.
  • The numbers of animals used, euthanized, and found dead (if any); the cause of death for all animals.
  • How frequently animal health and behavior were monitored.
  • All animal welfare considerations taken, including efforts to minimize suffering and distress, use of analgesics or anaesthetics, or special housing conditions.

If humane endpoints were not used, the manuscript should report:

  • A scientific justification for the study design, including the reasons why humane endpoints could not be used, and discussion of alternatives that were considered.
  • Whether the institutional animal ethics committee specifically reviewed and approved the anticipated mortality in the study design.

Observational and field studies

Methods sections for submissions reporting on any type of field study must include ethics statements that specify:

  • Permits and approvals obtained for the work, including the full name of the authority that approved the study; if none were required, authors should explain why
  • Whether the land accessed is privately owned or protected
  • Whether any protected species were sampled
  • Full details of animal husbandry, experimentation, and care/welfare, where relevant

Paleontology and archaeology research

Manuscripts reporting paleontology and archaeology research must include descriptions of methods and specimens in sufficient detail to allow the work to be reproduced. Data sets supporting statistical and phylogenetic analyses should be provided, preferably in a format that allows easy re-use. Read the policy.

Specimen numbers and complete repository information, including museum name and geographic location, are required for publication. Locality information should be provided in the manuscript as legally allowable, or a statement should be included giving details of the availability of such information to qualified researchers.

If permits were required for any aspect of the work, details should be given of all permits that were obtained, including the full name of the issuing authority. This should be accompanied by the following statement:

All necessary permits were obtained for the described study, which complied with all relevant regulations.

If no permits were required, please include the following statement:

No permits were required for the described study, which complied with all relevant regulations.

Manuscripts describing paleontology and archaeology research are subject to the following policies:

  • Sharing of data and materials. Any specimen that is erected as a new species, described, or figured must be deposited in an accessible, permanent repository (i.e., public museum or similar institution). If study conclusions depend on specimens that do not fit these criteria, the article will be rejected under PLOS ONE's data availability criterion.
  • Ethics. PLOS ONE will not publish research on specimens that were obtained without necessary permission or were illegally exported.

Systematic reviews and meta-analyses

A systematic review paper, as defined by The Cochrane Collaboration, is a review of a clearly formulated question that uses explicit, systematic methods to identify, select, and critically appraise relevant research, and to collect and analyze data from the studies that are included in the review. These reviews differ substantially from narrative-based reviews or synthesis articles. Statistical methods (meta-analysis) may or may not be used to analyze and summarize the results of the included studies.

Reports of systematic reviews and meta-analyses should include a completed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist and flow diagram to accompany the main text. Blank templates are available here:

Authors must also state in their “Methods” section whether a protocol exists for their systematic review, and if so, provide a copy of the protocol as supporting information and provide the registry number in the abstract.

If your article is a systematic review or a meta-analysis you should:

  • State this in your cover letter
  • Select “Research Article” as your article type when submitting
  • Include the PRISMA flow diagram as Fig 1 (required where applicable)
  • Include the PRISMA checklist as supporting information

Meta-analysis of genetic association studies

Manuscripts reporting a meta-analysis of genetic association studies must report results of value to the field and should be reported according to the guidelines presented in Systematic Reviews of Genetic Association Studies by Sagoo et al.

On submission, authors will be asked to justify the rationale for the meta-analysis and how it contributes to the base of scientific knowledge in the light of previously published results. Authors will also be asked to complete a checklist (DOCX) outlining information about the justification for the study and the methodology employed. Meta-analyses that replicate published studies will be rejected if the authors do not provide adequate justification.

Personal data from third-party sources

For all studies using personal data from internet-based and other third-party sources (e.g., social media, blogs, other internet sources, mobile phone companies), data must be collected and used according to company/website Terms and Conditions, with appropriate permissions. All data sources must be acknowledged clearly in the Materials and Methods section.

In the Ethics Statement, authors should declare any potential risks to individuals or individual privacy, or affirm that in their assessment, the study posed no such risks. In addition, the following Ethics and Data Protection requirements must be met.

For interventional studies, which impact participants’ experiences or data, the study design must have been prospectively approved by an Ethics Committee, and informed consent is required. The Ethics Committee may waive the requirement for approval and/or consent.

For observational studies in which personal experiences and accounts are not manipulated, consultation with an Ethics or Data Protection Committee is recommended. Additional requirements apply in the following circumstances:

  • If information used could threaten personal privacy or damage the reputation of individuals whose data are used, an Ethics Committee should be consulted and informed consent obtained or specifically addressed.
  • If authors accessed any personal identifying information, an Ethics or Data Protection Committee should oversee data anonymization. If data were anonymized and/or aggregated before access and analysis, informed consent is generally not required.
Note that Terms of Use contracts do not qualify as informed consent, even if they address the use of personal data for research. 

Cell lines

Authors reporting research using cell lines should state when and where they obtained the cells, giving the date and the name of the researcher, cell line repository, or commercial source (company) who provided the cells, as appropriate.

Authors must also include the following information for each cell line:

For de novo (new) cell lines, including those given to the researchers as a gift, authors must follow our policies for human subjects research or animal research, as appropriate. The ethics statement must include:

  • Details of institutional review board or ethics committee approval; AND
  • For human cells, confirmation of written informed consent from the donor, guardian, or next of kin

For established cell lines, the Methods section should include:

  • A reference to the published article that first described the cell line; AND/OR
  • The cell line repository or company the cell line was obtained from, the catalogue number, and whether the cell line was obtained directly from the repository/company or from another laboratory

Authors should check established cell lines using the ICLAC Database of Cross-contaminated or Misidentified Cell Lines to confirm they are not misidentified or contaminated. Cell line authentication is recommended – e.g., by karyotyping, isozyme analysis, or short tandem repeats (STR) analysis – and may be required during peer review or after publication.

Blots and gels

Please review PLOS ONE’s requirements for reporting blot and gel results and providing the underlying raw images.

Antibodies

Manuscripts reporting experiments using antibodies should include the following information:

  • The name of each antibody, a description of whether it is monoclonal or polyclonal, and the host species.
  • The commercial supplier or source laboratory.
  • The catalogue or clone number and, if known, the batch number.
  • The antigen(s) used to raise the antibody.
  • For established antibodies, a stable public identifier from the Antibody Registry.

The manuscript should also report the following experimental details:

  • The final antibody concentration or dilution.
  • A reference to the validation study if the antibody was previously validated. If not, provide details of how the authors validated the antibody for the applications and species used. 
We encourage authors to consider adding information on new validations to a publicly available database such as Antibodypedia or CiteAb.

Small and macromolecule crystal data

Manuscripts reporting new and unpublished three-dimensional structures must include sufficient supporting data and detailed descriptions of the methodologies used to allow the reproduction and validation of the structures. All novel structures must have been deposited in a community endorsed database prior to submission (please see our list of recommended repositories).

Small molecule single crystal data

Authors reporting X-Ray crystallographic structures of small organic, metal-organic, and inorganic molecules must deposit their data with the Cambridge Crystallographic Data Centre (CCDC), the Inorganic Crystal Structure Database (ICSD), or similar community databases providing a recognized validation functionality. Authors are also required to include the relevant structure reference numbers within the main text (e.g. the CCDC ID number), as well as the crystallographic information files (.cif format) as Supplementary Information, along with the checkCIF validation reports that can be obtained via the International Union of Crystallography (IUCr).

Macromolecular structures

Authors reporting novel macromolecular structures must have deposited their data prior to initial submission with the Worldwide Protein Data Bank (wwPDB), the Biological Magnetic Resonance Data Bank (BMRB), the Electron Microscopy Data Bank (EMDB), or other community databases providing a recognized validation functionality. Authors must include the structure reference numbers within the main text and submit as Supplementary Information the official validation reports from these databases.

Methods, software, databases, and tools

PLOS ONE will consider submissions that present new methods, software, databases, or tools as the primary focus of the manuscript if they meet the following criteria:

Utility
The tool must be of use to the community and must present a proven advantage over existing alternatives, where applicable. Recapitulation of existing methods, software, or databases is not useful and will not be considered for publication. Combining data and/or functionalities from other sources may be acceptable, but simpler instances (i.e. presenting a subset of an already existing database) may not be considered. For software, databases, and online tools, the long-term utility should also be discussed, as relevant. This discussion may include maintenance, the potential for future growth, and the stability of the hosting, as applicable.

Validation
Submissions presenting methods, software, databases, or tools must demonstrate that the new tool achieves its intended purpose. If similar options already exist, the submitted manuscript must demonstrate that the new tool is an improvement over existing options in some way. This requirement may be met by including a proof-of-principle experiment or analysis; if this is not possible, a discussion of the possible applications and some preliminary analysis may be sufficient.

Availability
If the manuscript’s primary purpose is the description of new software or a new software package, this software must be open source, deposited in an appropriate archive, and conform to the Open Source Definition. If the manuscript mainly describes a database, this database must be open-access and hosted somewhere publicly accessible, and any software used to generate a database should also be open source. If relevant, databases should be open for appropriate deposition of additional data. Dependency on commercial software such as Mathematica and MATLAB does not preclude a paper from consideration, although complete open source solutions are preferred. In these cases, authors should provide a direct link to the deposited software or the database hosting site from within the paper. If the primary focus of a manuscript is the presentation of a new tool, such as a newly developed or modified questionnaire or scale, it should be openly available under a license no more restrictive than CC BY.

Software submissions

Manuscripts whose primary purpose is the description of new software must provide full details of the algorithms designed. Describe any dependencies on commercial products or operating system. Include details of the supplied test data and explain how to install and run the software. A brief description of enhancements made in the major releases of the software may also be given. Authors should provide a direct link to the deposited software from within the paper.

Database submissions

For descriptions of databases, provide details about how the data were curated, as well as plans for long-term database maintenance, growth, and stability. Authors should provide a direct link to the database hosting site from within the paper.

New taxon names

Zoological names

When publishing papers that describe a new zoological taxon name, PLOS aims to comply with the requirements of the International Commission on Zoological Nomenclature (ICZN). Effective 1 January 2012, the ICZN considers an online-only publication to be legitimate if it meets the criteria of archiving and is registered in ZooBank, the ICZN's official registry.

For proper registration of a new zoological taxon, we require two specific statements to be included in your manuscript.

In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science Identifier (LSID), should be listed under the new species name, for example:

Anochetus boltoni Fisher sp. nov. urn:lsid:zoobank.org:act:B6C072CF-1CA6-40C7-8396-534E91EF7FBB

You will need to contact Zoobank to obtain a GUID (LSID). Please do this as early as possible to avoid delay of publication upon acceptance of your manuscript. It is your responsibility to provide us with this information so we can include it in the final published paper.

Please also insert the following text into the Methods section, in a sub-section to be called “Nomenclatural Acts”:

The electronic edition of this article conforms to the requirements of the amended International Code of Zoological Nomenclature, and hence the new names contained herein are available under that Code from the electronic edition of this article. This published work and the nomenclatural acts it contains have been registered in ZooBank, the online registration system for the ICZN. The ZooBank LSIDs (Life Science Identifiers) can be resolved and the associated information viewed through any standard web browser by appending the LSID to the prefix “http://zoobank.org/”. The LSID for this publication is: urn:lsid:zoobank.org:pub: XXXXXXX. The electronic edition of this work was published in a journal with an ISSN, and has been archived and is available from the following digital repositories: LOCKSS [author to insert any additional repositories].

All PLOS articles are deposited in LOCKSS. If your institute, or those of your co-authors, has its own repository, we recommend that you also deposit the published online article there and include the name in your article.

Botanical names

When publishing papers that describe a new botanical taxon, PLOS aims to comply with the requirements of the International Code of Nomenclature for algae, fungi, and plants (ICN). The following guidelines for publication in an online-only journal have been agreed such that any scientific botanical name published by us is considered effectively published under the rules of the Code. Please note that these guidelines differ from those for zoological nomenclature, and apply only to seed plants, ferns, and lycophytes.

Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or English. This does not affect the requirements for scientific names, which are still to be Latin.

Also effective January 2012, the electronic PDF represents a published work according to the ICN for algae, fungi, and plants. Therefore the new names contained in the electronic publication of PLOS article are effectively published under that Code from the electronic edition alone, so there is no longer any need to provide printed copies.

Additional information describing recent changes to the Code can be found here.

For proper registration of the new taxon, we require two specific statements to be included in your manuscript.

In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science Identifier (LSID), should be listed under the new species name, for example:

Solanum aspersum S.Knapp, sp. nov. [urn:lsid:ipni.org:names:77103633-1] Type: Colombia. Putumayo: vertiente oriental de la Cordillera, entre Sachamates y San Francisco de Sibundoy, 1600-1750 m, 30 Dec 1940, J. Cuatrecasas 11471 (holotype, COL; isotypes, F [F-1335119], US [US-1799731]).

Journal staff will contact IPNI to obtain the GUID (LSID) after your manuscript is accepted for publication, and this information will then be added to the manuscript during the production phase

In the Methods section, include a sub-section called “Nomenclature” using the following wording:

The electronic version of this article in Portable Document Format (PDF) in a work with an ISSN or ISBN will represent a published work according to the International Code of Nomenclature for algae, fungi, and plants, and hence the new names contained in the electronic publication of a PLOS article are effectively published under that Code from the electronic edition alone, so there is no longer any need to provide printed copies.

In addition, new names contained in this work have been submitted to IPNI, from where they will be made available to the Global Names Index. The IPNI LSIDs can be resolved and the associated information viewed through any standard web browser by appending the LSID contained in this publication to the prefix http://ipni.org/. The online version of this work is archived and available from the following digital repositories: [INSERT NAMES OF DIGITAL REPOSITORIES WHERE ACCEPTED MANUSCRIPT WILL BE SUBMITTED (LOCKSS etc)].

All PLOS articles are deposited in LOCKSS. If your institute, or those of your co-authors, has its own repository, we recommend that you also deposit the published online article there and include the name in your article.

Fungal names

When publishing papers that describe a new botanical taxon, PLOS aims to comply with the requirements of the International Code of Nomenclature for algae, fungi, and plants (ICN). The following guidelines for publication in an online-only journal have been agreed such that any scientific botanical name published by us is considered effectively published under the rules of the Code. Please note that these guidelines differ from those for zoological nomenclature.

Effective January 2012, the description or diagnosis of a new taxon can be in either Latin or English. This does not affect the requirements for scientific names, which are still to be Latin.

Also effective January 2012, the electronic PDF represents a published work according to the ICN for algae, fungi, and plants. Therefore the new names contained in the electronic publication of PLOS article are effectively published under that Code from the electronic edition alone, so there is no longer any need to provide printed copies.

Additional information describing recent changes to the Code can be found here.

For proper registration of the new taxon, we require two specific statements to be included in your manuscript.

In the Results section, the globally unique identifier (GUID), currently in the form of a Life Science Identifier (LSID), should be listed under the new species name, for example:

Hymenogaster huthii. Stielow et al. 2010, sp. nov. [urn:lsid:indexfungorum.org:names:518624]

You will need to contact either Mycobank or Index Fungorum to obtain the GUID (LSID). Please do this as early as possible to avoid delay of publication upon acceptance of your manuscript. It is your responsibility to provide us with this information so we can include it in the final published paper. Effective January 2013, all papers describing new fungal species must reference the identifier issued by a recognized repository in the protologue in order to be considered effectively published.

In the Methods section, include a sub-section called “Nomenclature” using the following wording. Note that this example is for taxon names submitted to MycoBank; please substitute appropriately if you have submitted to Index Fungorum using the prefix http://www.indexfungorum.org/Names/NamesRecord.asp?RecordID=.

The electronic version of this article in Portable Document Format (PDF) in a work with an ISSN or ISBN will represent a published work according to the International Code of Nomenclature for algae, fungi, and plants, and hence the new names contained in the electronic publication of a PLOS article are effectively published under that Code from the electronic edition alone, so there is no longer any need to provide printed copies.

In addition, new names contained in this work have been submitted to MycoBank from where they will be made available to the Global Names Index. The unique MycoBank number can be resolved and the associated information viewed through any standard web browser by appending the MycoBank number contained in this publication to the prefix http://www.mycobank.org/MB/. The online version of this work is archived and available from the following digital repositories: [INSERT NAMES OF DIGITAL REPOSITORIES WHERE ACCEPTED MANUSCRIPT WILL BE SUBMITTED (LOCKSS etc)].

All PLOS articles are deposited in LOCKSS. If your institute, or those of your co-authors, has its own repository, we recommend that you also deposit the published online article there and include the name in your article.

Qualitative research

Qualitative research studies use non-quantitative methods to address a defined research question that may not be accessible by quantitative methods, such as people's interpretations, experiences, and perspectives. The analysis methods are explicit, systematic, and reproducible, but the results do not involve numerical values or use statistics. Examples of qualitative data sources include, but are not limited to, interviews, text documents, audio/video recordings, and free-form answers to questionnaires and surveys.

Qualitative research studies should be reported in accordance to the Consolidated criteria for reporting qualitative research (COREQ) checklist or Standards for reporting qualitative research (SRQR) checklist. Further reporting guidelines can be found in the Equator Network's Guidelines for reporting qualitative research.

You may be eligible for APC support

Many institutional partners globally have publishing agreements with PLOS to allow their corresponding authors to publish with reduced or no APCs. To determine if your corresponding author is eligible, please visit our institutional partners page to determine what kind of agreement your institution has with PLOS.

If your corresponding author is affiliated with a participating institution, they must follow the instructions below to demonstrate eligibility.

If your corresponding author is not from a participating institution and requires assistance paying publishing fees, please consider applying for a fee waiver at submission.